180 Life Sciences (ATNF) Competitors $10.70 +0.46 (+4.49%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$11.00 +0.30 (+2.77%) As of 08/13/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. MGX, ASRT, CABA, INMB, STRO, GNTA, ARTV, FBRX, IMMX, and MNOVShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Metagenomi (MGX), Assertio (ASRT), Cabaletta Bio (CABA), INmune Bio (INMB), Sutro Biopharma (STRO), Genenta Science (GNTA), Artiva Biotherapeutics (ARTV), Forte Biosciences (FBRX), Immix Biopharma (IMMX), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Its Competitors Metagenomi Assertio Cabaletta Bio INmune Bio Sutro Biopharma Genenta Science Artiva Biotherapeutics Forte Biosciences Immix Biopharma MediciNova Metagenomi (NASDAQ:MGX) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Which has higher earnings and valuation, MGX or ATNF? 180 Life Sciences has lower revenue, but higher earnings than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than 180 Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$52.29M1.39-$78.06M-$2.36-0.82180 Life SciencesN/AN/A-$6.17M-$15.07-0.71 Do analysts prefer MGX or ATNF? Metagenomi presently has a consensus target price of $13.00, indicating a potential upside of 570.10%. Given Metagenomi's stronger consensus rating and higher possible upside, equities analysts plainly believe Metagenomi is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, MGX or ATNF? Metagenomi has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Do insiders & institutionals have more ownership in MGX or ATNF? 4.1% of 180 Life Sciences shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by insiders. Comparatively, 38.2% of 180 Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is MGX or ATNF more profitable? 180 Life Sciences has a net margin of 0.00% compared to Metagenomi's net margin of -257.99%. Metagenomi's return on equity of -36.28% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-257.99% -36.28% -26.02% 180 Life Sciences N/A -141.25%-80.77% Does the media prefer MGX or ATNF? In the previous week, 180 Life Sciences had 3 more articles in the media than Metagenomi. MarketBeat recorded 10 mentions for 180 Life Sciences and 7 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.45 beat 180 Life Sciences' score of 0.42 indicating that Metagenomi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 180 Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMetagenomi beats 180 Life Sciences on 8 of the 15 factors compared between the two stocks. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.84M$3.04B$5.55B$9.83BDividend YieldN/A2.27%4.62%4.11%P/E Ratio-0.7120.6730.1526.03Price / SalesN/A367.61462.89105.43Price / CashN/A42.0537.7558.93Price / Book12.027.638.476.06Net Income-$6.17M-$54.65M$3.26B$265.11M7 Day Performance198.88%3.95%3.56%2.90%1 Month Performance1,081.02%11.46%5.97%3.99%1 Year Performance514.94%13.04%42.70%26.92% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life Sciences0.9666 of 5 stars$10.70+4.5%N/A+514.9%$61.84MN/A-0.717News CoverageGap UpHigh Trading VolumeMGXMetagenomi3.1668 of 5 stars$1.83-4.7%$13.00+610.4%-40.3%$71.77M$52.29M-0.87236News CoverageEarnings ReportASRTAssertio2.1488 of 5 stars$0.73-0.5%$2.63+262.1%-26.8%$69.82M$124.96M-2.2720News CoverageEarnings ReportAnalyst ForecastCABACabaletta Bio2.1457 of 5 stars$1.33-2.2%$14.43+984.9%-62.5%$69.01MN/A-0.4950Earnings ReportUpcoming EarningsGap UpINMBINmune Bio2.8894 of 5 stars$2.40-6.3%$18.40+666.7%-63.3%$68.06M$10K-0.9710Earnings ReportSTROSutro Biopharma3.9127 of 5 stars$0.77-3.7%$6.11+691.4%-76.0%$68.02M$62.04M-0.31240News CoverageEarnings ReportAnalyst ForecastGNTAGenenta Science2.7488 of 5 stars$3.54-4.7%$25.00+607.2%-28.9%$67.87MN/A0.007Positive NewsGap UpHigh Trading VolumeARTVArtiva Biotherapeutics2.5044 of 5 stars$2.56-7.2%$17.80+595.3%-76.2%$67.42M$250K0.0081Trending NewsEarnings ReportAnalyst RevisionFBRXForte Biosciences3.1659 of 5 stars$10.51+3.2%$61.00+480.4%+62,355.7%$66.99MN/A-0.655News CoverageGap DownIMMXImmix Biopharma3.1226 of 5 stars$2.32-2.9%$7.00+201.7%+25.3%$66.63MN/A-3.019Earnings ReportMNOVMediciNova2.7138 of 5 stars$1.33-1.5%$7.00+426.3%+12.4%$66.21M$1M-5.7810Upcoming EarningsGap Down Related Companies and Tools Related Companies MGX Competitors ASRT Competitors CABA Competitors INMB Competitors STRO Competitors GNTA Competitors ARTV Competitors FBRX Competitors IMMX Competitors MNOV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access